<DOC>
	<DOCNO>NCT00798460</DOCNO>
	<brief_summary>The purpose study determine optimal antiviral treatment lamivudine resistant hepatitis B patient .</brief_summary>
	<brief_title>Efficacy Clevudine Plus Lamivudine Lamivudine-resistant Chronic Hepatitis B Patients</brief_title>
	<detailed_description>Lamivudine adefovir combination therapy know effective antiviral therapy lamivudine resistant chronic hepatitis B patient . It superior adefovir monotherapy since incidence viral breakthrough combination therapy use less adefovir monotherapy lamivudine resistant chronic hepatitis B patient . Clevudine , market Korea , nucleoside analogue unnatural beta-L configuration potent activity HBV . It demonstrate potent antiviral efficacy significant biochemical improvement 24 week therapy . We hypothesize clevudine plus adefovir combination therapy lamivudine resistant patient might effective lamivudine plus adefovir combination therapy . In detail , design perform clinical study compare combination clevudine adefovir lamivudine plus adefovir lamivudine resistant chronic hepatitis B patient . Total treatment duration group 12 month , compare efficacy antiviral effect drug .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBsAg positive antiHBs negative 6 month YMDD mutation ( + ) lamivudine therapy Serum ALT two time upper normal value HAV IgM Ab + and/or HCV Ab+ and/or HDV Ab and/or HIV Av+ The sign decompensated liver disease Pregnant lactate woman The history hemoglobinopathy , autoimmune hepatitis , alcoholic liver disease Hemoglobin le 8 g/dL ( male ) , 7.5g/dL ( female ) neutrophil count le 1500/mm3 platelet count le 50,000/mm3 Serum creatinine 1.5 time upper normal limit value The sign malignancy suggestive malignancy history malignancy , recurrence rate within 2 year 20 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>lamivudine resistance</keyword>
	<keyword>clevudine</keyword>
</DOC>